Skip to main content

Table 2 Cellular therapies

From: Novel and emerging therapies for B cell lymphoma

Cellular therapy N Patient population ORR CR Grade 3 CRS/NT Grade 3 AE Ref
ET190L1-ArtemisTM Therapy 21 DLBCL, FL,MCL, SLL/CLL, splenic MZL 52% 24% None Lymphopenia, neutropenia, tremor, fever, rash [19]
Bispecific CAR (CD-19/CD-20) 7 DLBCL, ALL 60% (DLBCL) 40% (DLBCL) None None [23]
Bispecific CAR (CD-19/CD-20) 6 DLBCL, FL, MCL,CLL 50% 33% None None [24]
Bispecific CAR (CD-19/CD-22) 6 DLBCL, tFL, tMZL 80% 40% 1 patient (20%)—NT Neutropenia, thrombocytopenia, hypophosphatemia, neurotoxicity [25]
Armored CAR T cells 25 DLBCL ,CLL, tFL, FL, WM 72% 57% 2 patients (8%)—NT Neurotoxicity [26]
ACTR 087 7 r/r NHL 50% 33% None Neutropenia, leukopenia [27]
ACTR 707 6 DLBCL, FL NA 50% None Febrile neutropenia [28]
  1. Abbreviations: N number of patients, ORR overall response rate, CR complete response rate, CRS cytokine release syndrome, NT neurotoxicity, AE adverse events, DLBCL diffuse large B cell lymphoma, CLL chronic leukemic leukemia, tFL transformed follicular lymphoma, FL follicular lymphoma, WM Waldenström’s macroglobulinemia, MCL mantle cell lymphoma, tMZL transformed marginal zone lymphoma, ALL acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MZL marginal zone lymphoma, NA data unavailable